Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir
Elvitegravir, cobicistat, emtricitabine and tenofovir is a four-drug, once-daily combination tablet (sold as Genvoya and Stribild) that serves as a complete regimen for treating HIV-1 infection.
Built from the FDA-approved label, dated Feb 3, 2025 · How this page is built
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
If you have both HIV and hepatitis B and stop this medicine, your hepatitis B can suddenly get much worse. Severe flare-ups have been reported in people who stopped medicines containing emtricitabine or tenofovir. This can affect liver function seriously.
Do not stop on your own. If you do stop, your doctor should monitor your liver with exams and blood tests for at least several months. Hepatitis B treatment may be needed.
⚡ Quick answers about Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir
What is this medicine for?
It treats HIV-1 infection as a complete regimen in one tablet. Genvoya and Stribild are the two brands. They differ by the age and weight of who can take them, so your prescriber picks the one that fits.
See it in the FAQ →How do I take it?
Take one tablet by mouth once a day with food. Follow your prescriber's directions. Do not add other HIV medicines unless your prescriber tells you to.
See it in the FAQ →What side effects should I expect?
Nausea is the most common one. Diarrhea, headache and tiredness can happen too. Call your doctor for bone or muscle pain, signs of kidney or liver trouble, or anything that worries you.
See it in the FAQ →What if I have hepatitis B too?
Do not stop this medicine on your own. Stopping can cause a severe hepatitis B flare. If you do stop, your doctor should watch your liver closely for at least several months.
See it in the FAQ →🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 2 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
How we combine label and product data →📖 Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir: Patient Information Guide
A plain-language walkthrough of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
What Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir is used for
▾
This four-drug combination treats HIV-1 infection as a complete regimen.
- Genvoya: adults and children weighing at least 25 kg, either new to HIV treatment or switching from a stable regimen with suppressed virus.
- Stribild: adults and children 12 and older weighing at least 35 kg, either new to HIV treatment or switching from a stable regimen with suppressed virus.
- Switching is for people with virus under 50 copies/mL for at least 6 months, no treatment failure history, and no known resistance to its components.
How Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir works
▾
Elvitegravir blocks HIV integrase, which stops the virus from inserting its DNA into your cells. Emtricitabine and tenofovir block reverse transcriptase, which stops the virus from copying its genetic material.
Cobicistat blocks CYP3A, a liver enzyme that breaks down elvitegravir. This keeps elvitegravir levels higher. The two tablets differ in the tenofovir form: Genvoya uses tenofovir alafenamide and Stribild uses tenofovir disoproxil fumarate.
How Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir is taken (dosage)
▾
Both Genvoya and Stribild are one tablet by mouth once a day with food. Your prescriber will check for hepatitis B and monitor your kidneys before and during treatment.
- Genvoya: on dialysis days, take it after your dialysis session.
- Stribild: not for starting if kidney function is reduced, and it is stopped if kidney function falls too low.
Follow your prescriber and the label for any missed-dose questions.
Dosing details from the FDA-approved label
From the Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Genvoya: adults and pediatric patients with body weight at least 25 kg and creatinine clearance greater than or equal to 30 mL per minute
- One tablet (150 mg EVG, 150 mg COBI, 200 mg FTC, 10 mg TAF) taken orally once daily with food
- Taken with food
- Genvoya: adults with creatinine clearance below 15 mL per minute who are receiving chronic hemodialysis
- One tablet taken orally once daily with food
- On days of hemodialysis, administer after completion of hemodialysis treatment
- Genvoya: severe renal impairment (estimated creatinine clearance 15 to below 30 mL per minute) or ESRD (below 15 mL per minute) not receiving chronic hemodialysis
- Not recommended
- Not recommended in these patients
- Genvoya: severe hepatic impairment (Child-Pugh Class C)
- Not recommended
- Genvoya: pregnancy
- Not recommended during pregnancy
- Should not be initiated in pregnant individuals
- An alternative regimen is recommended for individuals who become pregnant during therapy
- Stribild: adults and pediatric patients 12 years of age and older with body weight at least 35 kg and creatinine clearance greater than or equal to 70 mL per minute
- One tablet (150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, 300 mg TDF) taken orally once daily with food
- Taken with food
- Stribild: renal impairment
- Initiation in patients with estimated creatinine clearance below 70 mL per minute is not recommended
- Discontinue if estimated creatinine clearance declines below 50 mL per minute during treatment
- No data available for dose recommendations for pediatric patients with renal impairment
- Stribild: severe hepatic impairment
- Not recommended
- Stribild: pregnancy
- Not recommended during pregnancy
- Should not be initiated in pregnant individuals
- An alternative regimen is recommended for individuals who become pregnant during therapy
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION Testing: Prior to or when initiating GENVOYA test for hepatitis B virus infection. Prior to or when initiating GENVOYA, and during treatment on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus. ( 2.1 ) Recommended dosage in adult and pediatric patients weighing at least 25 kg: One tablet taken orally once daily with food in patients with body weight at least 25 kg and a creatinine clearance greater than or equal to 30 mL per minute, or in adult patients with creatinine clearance less than 15 mL per minute who are receiving chronic hemodialysis. On days of hemodialysis, administer GENVOYA after hemodialysis. ( 2.2 ) Renal impairment: GENVOYA is not recommended in patients with estimated creatinine clearance of 15 to below 30 mL per minute, or below 15 mL per minute who are not receiving chronic hemodialysis. ( 2.3 ) Hepatic impairment: GENVOYA is not recommended in patients with severe hepatic impairment. ( 2.4 ) 2.1 Testing When Initiating and During Treatment with GENVOYA Prior to or when initiating GENVOYA, test patients for hepatitis B virus infection [see Warnings and Precautions (5.1) ] . Prior to or when initiating GENVOYA, and during treatment with GENVOYA on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus [see Warnings and Precautions (5.4) ] . 2.2 Recommended Dosage in Adults and Pediatric Patients Weighing at Least 25 kg GENVOYA is a four-drug fixed dose combination product containing elvitegravir (EVG), cobicistat (COBI), emtricitabine (FTC), and tenofovir alafenamide (TAF). The recommended dosage of GENVOYA is one tablet containing 150 mg EVG,150 mg COBI, 200 mg FTC, and 10 mg TAF taken orally once daily with food in: adults and pediatric patients with body weight at least 25 kg and creatinine clearance greater than or equal to 30 mL per minute; or adults with creatinine clearance below 15 mL per minute who are receiving chronic hemodialysis.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir side effects in detail
▾
Common side effects
- Nausea (the most common)
- Diarrhea
- Headache
- Fatigue
When to get medical help
- Call your doctor if you have HIV and hepatitis B and stopped this medicine. Hepatitis B can flare up severely.
- Get help if you have bone pain, pain in your arms or legs, fractures, or muscle pain or weakness. These can be signs of kidney tubule problems.
- Report symptoms of lactic acidosis (too much acid in the blood) or serious liver problems right away.
- Tell your doctor about new symptoms of infection or inflammation after starting treatment. This can be immune reconstitution syndrome.
- Report any signs of worsening kidney function, such as changes in your kidney tests.
Most people tolerate it fairly well. Common side effects include:
- Nausea (most common)
- Diarrhea
- Headache
- Fatigue
Get medical help for signs of kidney problems, lactic acidosis, liver trouble, or a hepatitis B flare after stopping.
Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir warnings and precautions
▾
- Hepatitis B flare after stopping (boxed warning): can be severe in people with HIV and hepatitis B.
- Kidney problems: including acute kidney failure and Fanconi syndrome. Avoid nephrotoxic drugs such as high-dose or multiple NSAIDs.
- Lactic acidosis and severe liver enlargement: reported with nucleoside analogs.
- Bone loss: tenofovir disoproxil fumarate (in Stribild) has been linked to lower bone density. Bone density checks may be considered if you are at risk.
- Immune reconstitution syndrome: inflammation from old infections as your immune system recovers.
- Drug interactions: can cause serious side effects or loss of effect.
Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir interactions: what it interacts with
▾
Cobicistat affects how the body handles many other drugs, so always review your medicines.
- Contraindicated: alfuzosin, carbamazepine, phenobarbital, phenytoin, rifampin, lurasidone, pimozide, St. John's wort.
- Stribild also: ergot drugs, lomitapide, lovastatin, simvastatin, triazolam, oral midazolam, and sildenafil as Revatio.
- Other HIV medicines: not recommended, since this is a complete regimen.
- Blood thinners such as rivaroxaban, apixaban and warfarin: bleeding risk or monitoring needed.
- Colchicine, antiarrhythmics, antidepressants, quetiapine: levels can rise and doses may need adjusting.
- NSAIDs and kidney-affecting drugs (such as acyclovir, valacyclovir and gentamicin): may raise kidney risk.
Interactions listed in the FDA-approved label
From the Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Other antiretroviral medications for HIV-1: Genvoya is a complete regimen for HIV-1 infection, so coadministration with other antiretrovirals should be avoided. Should not be administered with other antiretroviral medications for treatment of HIV-1 infection
- Alfuzosin: Increases alfuzosin, with potential for serious and/or life-threatening reactions such as hypotension. Coadministration is contraindicated
- Antiarrhythmics (e.g., amiodarone, bepridil, digoxin, disopyramide, flecainide, systemic lidocaine, mexiletine, propafenone, quinidine): Increases concentrations of antiarrhythmics and digoxin. Caution is warranted and therapeutic concentration monitoring, if available, is recommended
- Clarithromycin, telithromycin: Increases clarithromycin, telithromycin and cobicistat. CLcr 60 mL/minute or greater: no dosage adjustment of clarithromycin. CLcr between 50 mL/minute and 60 mL/minute: reduce clarithromycin dosage by 50%.
- Rivaroxaban: Increases rivaroxaban and may lead to an increased bleeding risk. Coadministration is not recommended
- Warfarin: Effect on warfarin is unknown. Monitor the international normalized ratio (INR)
- Carbamazepine, phenobarbital, phenytoin: Decreases elvitegravir, cobicistat and TAF, with potential for loss of therapeutic effect and development of resistance. Coadministration is contraindicated
- Ketoconazole, itraconazole, voriconazole: Increases elvitegravir, cobicistat and the antifungal concentrations. Maximum daily dosage of ketoconazole or itraconazole should not exceed 200 mg per day; assess benefit/risk to justify voriconazole use
- Rifampin: Decreases elvitegravir, cobicistat and TAF, with potential for loss of therapeutic effect and development of resistance. Coadministration is contraindicated
- Lurasidone, pimozide: Increases lurasidone or pimozide, with potential for serious and/or life-threatening reactions. Coadministration is contraindicated
Read the label’s full interactions text
7 DRUG INTERACTIONS GENVOYA should not be administered with other antiretroviral medications for treatment of HIV-1 infection. ( 7.1 ) GENVOYA can alter the concentration of drugs metabolized by CYP3A or CYP2D6. Drugs that induce CYP3A can alter the concentrations of one or more components of GENVOYA. Consult the full prescribing information prior to and during treatment for potential drug-drug interactions. ( 4 , 7.2 , 7.3 , 12.3 ) 7.1 Not Recommended with Other Antiretroviral Medications GENVOYA is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration of GENVOYA with other antiretroviral medications for treatment of HIV-1 infection should be avoided. Complete information regarding potential drug-drug interactions with other antiretroviral medications is not provided [see Contraindications (4) , Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ] . 7.2 Potential for GENVOYA to Affect Other Drugs Cobicistat, a component of GENVOYA, is an inhibitor of CYP3A and CYP2D6 and an inhibitor of the following transporters: P-glycoprotein (P-gp), BCRP, OATP1B1 and OATP1B3. Thus, coadministration of GENVOYA with drugs that are primarily metabolized by CYP3A or CYP2D6, or are substrates of P-gp, BCRP, OATP1B1 or OATP1B3 may result in increased plasma concentrations of such drugs . Coadministration of GENVOYA with drugs that have active metabolite(s) formed by CYP3A may result in reduced plasma concentration of these active metabolite(s) (see Table 5 ). Elvitegravir is a modest inducer of CYP2C9 and may decrease the plasma concentrations of CYP2C9 substrates. TAF is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or UGT1A1. TAF is a weak inhibitor of CYP3A in vitro . TAF is not an inhibitor or inducer of CYP3A in vivo . 7.3 Potential for Other Drugs to Affect One or More Components of GENVOYA Elvitegravir and cobicistat, components of GENVOYA, are metabolized by CYP3A.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir
▾
- Hepatitis B testing is needed before starting.
- Pregnancy: not recommended, and treatment should not be started during pregnancy.
- Breastfeeding is not recommended because of the chance of passing on HIV (Genvoya label).
- Severe liver impairment: not recommended.
- Kidney impairment: limits apply to both brands.
- Children: weight and age limits differ by brand.
- Bone fracture history or osteoporosis risk: tell your doctor.
Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir overdose: if you take too much
▾
No data are available on overdose of Stribild. If an overdose happens, the person should be monitored for signs of toxicity and given general supportive care. Emtricitabine and tenofovir can be partly removed by hemodialysis.
Pharmacodynamics: what Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir does in the body
▾
Cobicistat lowers estimated creatinine clearance a bit by blocking creatinine secretion in the kidney. Actual kidney filtration was not changed in the study, and the effect reversed after stopping. At the dose used here, cobicistat is unlikely to cause meaningful changes in heart electrical timing (PR interval).
Pharmacokinetics: how your body processes Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir
▾
Genvoya should be taken with food because food raises elvitegravir levels. Elvitegravir and cobicistat are broken down by CYP3A. Emtricitabine and tenofovir are cleared mainly by the kidneys. The active form of tenofovir stays inside cells for a long time, with a half-life of 150 to 180 hours.
How to store Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir
▾
Store at 25 °C (77 °F), excursions permitted to 15–30 °C (59–86 °F) (see USP Controlled Room Temperature).
📄 Written from Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir — the kind of thing our pharmacy team would talk through with you at the counter.
What is this medicine for?
▾
How do I take it?
▾
What side effects should I expect?
▾
What if I have hepatitis B too?
▾
Can I take my other medicines with it?
▾
Is it safe in pregnancy?
▾
Is Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir available over the counter?
▾
When was Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir first available?
▾
Who makes Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir?
▾
💬 Answers drafted from Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 More about Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir on HelloPharmacist
💊 Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir forms and strengths (how it comes)
Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Tablet
How this form is used
- Genvoya is a complete regimen for HIV-1 infection in adults and children weighing at least 25 kg.
- Stribild is a complete regimen for HIV-1 infection in adults and children 12 and older weighing at least 35 kg.
- Genvoya is taken as one tablet by mouth once daily with food. On hemodialysis days, take it after dialysis.
- Stribild is taken as one tablet by mouth once daily with food.
- Stribild should not be started with creatinine clearance below 70 mL/min and should be stopped if it falls below 50.
📊 Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir on the U.S. market: products, makers and brands
How Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
2 companies list 6 Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2012. Brand names on the directory include Stribild, Genvoya; the rest are generics.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir is used (Medicaid data)
A general measure of how commonly Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir prescribed? Of the 1,599 medications we measure, Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir ranks #572 by Medicaid prescriptions — more than 64% of them.
Utilization by Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
cobicistat 150 MG / elvitegravir 150 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet
Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1306292
Other Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir products — combination packs and listings not yet matched to a specific clinical product (kept visible so every prescription is accounted for)
Summed across the 1 of 3 listed NDC products with Medicaid activity.
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 2 of 6 listed Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir NDCs with Medicaid activity.
🔍 Compare Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir products
A representative set of FDA-listed product records for Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| ELVITEGRAVIR 150 mg/1; COBICISTAT 150 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR ALAFENAMIDE FUMARATE 10 mg | Oral | Gilead Sciences, Inc. | NDA | View NDC → |
| ELVITEGRAVIR 150 mg/1; COBICISTAT 150 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg | Oral | Gilead Sciences, Inc. | NDA | View NDC → |
| 150; 150; 200; 10 mg/1; mg/1; mg/1; mg | Oral | Gilead Sciences, Inc. | NDA | View NDC → |
| 150; 150; 200; 300 mg/1; mg/1; mg/1; mg | Oral | Gilead Sciences, Inc. | NDA | View NDC → |
| ELVITEGRAVIR 150 mg/1; COBICISTAT 150 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR ALAFENAMIDE FUMARATE 10 mg | — | Patheon Inc. | DRUG FOR FURTHER PROCESSING | View NDC → |
| ELVITEGRAVIR 150 mg/1; COBICISTAT 150 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg | — | Patheon Inc. | DRUG FOR FURTHER PROCESSING | View NDC → |
Showing 6 of 6 products — FDA National Drug Code Directory. See every product, package size and price: browse all 6 Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir NDCs →
📈 Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir FDA approval history
How Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
📦 Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir supply and shortage status
Whether Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir brand names
Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir is sold under 2 brand names in the FDA directory — Stribild, Genvoya. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
🏭 Who makes Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir: manufacturers and labelers
2 companies list Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir products with the FDA. By number of product records, the largest are Gilead Sciences, Inc., Patheon Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir drug class (RxNorm)
Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir belongs to the Cytochrome P450 3A Inhibitor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Sources for this Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 2 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Gilead Sciences, Inc. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.